Bone Biologics (BBLGW) Share-based Compensation (2014 - 2026)

Bone Biologics (BBLGW) has reported Share-based Compensation for 13 consecutive years, with $106479.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 21.2% year-over-year to $106479.0 in Q2 2026; TTM through Jun 2026 was $106479.0, a 21.2% increase from a year earlier, with the FY2025 full-year figure at $256358.0, up 35.77% from the prior year.
• Share-based Compensation was $106479.0 for Q2 2026 at Bone Biologics, up from $45674.0 in the prior quarter.
• Over five years, Share-based Compensation peaked at $509454.0 in Q1 2023 and troughed at $16995.0 in Q2 2023.
• A 5-year average of $181789.4 and a median of $100754.0 in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation jumped 6010.17% in 2022 and sank 95.03% in 2023, its largest moves.
• Over 5 years, Share-based Compensation stood at $62507.0 in 2022, then grew by 13.81% to $71139.0 in 2023, then jumped by 41.63% to $100754.0 in 2024, then slumped by 54.67% to $45674.0 in 2025, then surged by 133.13% to $106479.0 in 2026.
• The last three Share-based Compensation figures came in at $106479.0 (Q2 2026), $45674.0 (Q4 2025), and $87856.0 (Q3 2025), per Business Quant data.